Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

1.6K
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
1.6K
Viral Recombination00:57

Viral Recombination

24.7K
Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
24.7K
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

603
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
603
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

1.8K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Friend or foe? IFNλ drives fibrosis.

The Journal of experimental medicine·2026
Same author

No-known-vector flaviviruses exhibit diverse replication and virulence phenotypes in mice.

bioRxiv : the preprint server for biology·2026
Same author

SARS-CoV-2-induced dysregulation in ADAR editing patterns persists post viral clearance in individuals with mild COVID-19.

Frontiers in cellular and infection microbiology·2026
Same author

Systematic comparison of triglyceride-glucose (TYG)-index with other mortality predictive models in obese patients with different mortality rates.

Cardiovascular diabetology·2026
Same author

Plasma signals of lung tumor promotion for molecular cancer prevention.

Cell·2026
Same author

A glycan-based adjuvant expands the breadth and duration of protection of mRNA-based vaccines.

Nature immunology·2026

Related Experiment Video

Updated: Dec 24, 2025

Rescue of Recombinant Newcastle Disease Virus from cDNA
10:55

Rescue of Recombinant Newcastle Disease Virus from cDNA

Published on: October 11, 2013

19.9K

COVID-19 and emerging viral infections: The case for interferon lambda.

Ludmila Prokunina-Olsson1, Noémie Alphonse2,3, Ruth E Dickenson2

  • 1Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.

The Journal of Experimental Medicine
|April 15, 2020
PubMed
Summary

Type III interferons (IFN-λ) show promise for managing viral infections like COVID-19. This viewpoint discusses the potential benefits and limitations of using IFN-λ for prevention and treatment.

More Related Videos

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.7K
Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

12.4K

Related Experiment Videos

Last Updated: Dec 24, 2025

Rescue of Recombinant Newcastle Disease Virus from cDNA
10:55

Rescue of Recombinant Newcastle Disease Virus from cDNA

Published on: October 11, 2013

19.9K
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.7K
Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

12.4K

Area of Science:

  • Immunology
  • Virology
  • Infectious Diseases

Background:

  • The emergence of coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, highlighted the need for effective antiviral strategies.
  • Type III interferons (IFN-λ) are recognized for their crucial role in antiviral immunity, particularly at mucosal surfaces.

Purpose of the Study:

  • To present an expert opinion on the potential benefits of using IFN-λ in managing viral infections.
  • To discuss the limitations and challenges associated with the therapeutic application of IFN-λ.
  • To explore the role of IFN-λ in the context of emerging viral threats like SARS-CoV-2.

Main Methods:

  • This is a viewpoint article, not based on original experimental data.
  • The authors synthesize existing scientific literature and expert knowledge on IFN-λ and viral infections.
  • The discussion focuses on the immunological properties and therapeutic potential of IFN-λ.

Main Results:

  • IFN-λ exhibits potent antiviral activity, particularly in respiratory tissues, making it a relevant candidate for treating infections like COVID-19.
  • Potential benefits include targeted action with fewer systemic side effects compared to other interferon types.
  • Limitations may involve delivery methods, specific viral evasion mechanisms, and the need for further clinical validation.

Conclusions:

  • IFN-λ represents a promising therapeutic avenue for preventing, limiting, and treating viral respiratory infections, including those caused by SARS-CoV-2.
  • Further research and clinical trials are necessary to fully elucidate the efficacy and safety of IFN-λ-based therapies.
  • Understanding the precise mechanisms and optimizing the application of IFN-λ are key to harnessing its full potential in infectious disease management.